CagriReta Dual Injection Pen Kit — Retatrutide + Cagrilintide Dual Protocol

Our most advanced quad-pathway metabolic combination — pairing triple-agonist Retatrutide (40mg) with long-acting amylin analogue Cagrilintide (4mg) for complete GLP-1, GIP, Glucagon, and Amylin receptor coverage.

Analytical Specifications & HPLC Purity

  • Batch ID: SYN-26CR-9902N (RP-HPLC Purity: 99.58%)
  • CAS / Formula: 2381089-83-2 / 1415456-99-3 | C221H342N46O68 + C194H312N54O59S2 (4731.3 + 4409.0 g/mol)
  • Format: 40mg + 4mg Dual Kit | 1 click = 0.1667 mg
  • Storage: 2°C – 8°C (Refrigerated) | Half-life: ~6–8 days

Kit Contents

  • 1x Pen 1: Retatrutide 40mg System (4 x 10mg Cartridges)
  • 1x Pen 2: Cagrilintide 4mg Precision Pen
  • 20x Ultra-Fine 31G 4mm Siliconized Micro-Needles
  • 1x Executive Dual-Pen Presentation Case & Verification Seal

60-Unit Pen Titration & Click Schedule

WeeksDoseClicksPhase
Weeks 1–42.0 mg Reta + 0.25 mg Cagri12u Reta / 4u CagriQuad-Pathway Onboarding
Weeks 5–84.0 mg Reta + 0.50 mg Cagri24u Reta / 8u CagriMetabolic & Amylin Synergy
Weeks 9–126.0 mg Reta + 1.00 mg Cagri36u Reta / 15u CagriAdvanced Lipolytic Phase
Week 13+8.0–10.0 mg Reta + 1.50 mg Cagri48–60u Reta / 23u CagriPeak Quad-Agonist Protocol